Sign in
WithdrawnPhase 3

Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform

Key facts

Who runs it
Margaret Ragni
Where
Pittsburgh, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 3
Started
Aug 2020
Expected to end
Jul 2027
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Eloctate Prophylaxis
  • Emicizumab Prophylaxis
  • Eloctate ITI plus Emicizumab
  • Eloctate ITI
Record updated
20 August 2019
Why it stopped
The trial was revised to be two protocols, one Prevention, one Eradication Trials.

Who can take part

Age
4 months to 99 years
Sex
Men only
Healthy volunteers
Cannot take part
Show the full registry criteria (29)Hide the full registry criteria

Other criteria

  • Prevention Trial, Inclusion Criteria:
  • Male children >/= 4 months of age
  • Severe hemophilia A (FVIII < 0.01 U/ml)
  • No previous bleed or surgery requiring treatment (except circumcision)
  • No previous factor VIII product (except for circumcision)
  • Willingness to comply with weekly prophylaxis for 48 weeks
  • Willingness of parent/caregiver to keep a personal diary of bleeding frequency and factor treatment
  • Willingness to make monthly visits and coagulation testing at weeks 4, 12, 24, 36, and 48 (end of study); Prevention Trial, Exclusion Criteria:
  • Acquired hemophilia
  • Any bleeding disorder other than hemophilia A
  • Treatment with clotting factor previously, other than circumcision
  • Presence of an inhibitor to factor VIII
  • Use of an experimental drug(s)
  • Surgery anticipated in the next 48 weeks
  • Life expectancy less than 5 years
  • Inability to comply with study requirements; Eradication Trial, Inclusion Criteria:
  • Male adults or children with no age limitation
  • Severe hemophilia A (FVIII <0.01 U/ml)
  • Presence of an inhibitor to FVIII (anti-FVIII > 5.0 B.U.)
  • Willingness to comply with study drugs for up to 48 weeks
  • Willingness to keep a personal diary of bleed frequency and drug treatment
  • Willingness to make monthly visits and coagulation testing at weeks 4, 12, 24, 36, and 48 (end of study); Eradication Trial, Exclusion Criteria:
  • Acquired hemophilia
  • Any bleeding disorder other than hemophilia A
  • Current use of Emicizumab, or if used, > 8 weeks since last treatment
  • Use of an experimental drug(s)
  • Surgery anticipated in the next 48 weeks
  • Life expectancy less than 5 years
  • Inability to copy with study requirements

Where in United States

  • Hemophilia Center of Western PennsylvaniaPittsburgh, United States

About the trial

What the trial wants to find out

This study will evaluate if Eloctate is superior to Emicizumab in reducing inhibitors in children with severe hemophilia when given before the first bleed (preemptive) and continued weekly to prevent bleeds (prophylaxis); and whether Eloctate immune tolerance induction (ITI) plus emicizumab is superior to Eloctate ITI alone in eradicating inhibitor formation in children and adults with severe hemophilia A.

The 4 groups in the trial

  • Eloctate ProphylaxisTreatment being tested

    Prevention Trial, Arm A: rFVIIIFc (Eloctate) 65 IU/kg weekly will be administered by intravenous infusion in previously untreated children with severe hemophilia A beginning before the first bleed and continued for up to 48 weeks.

  • Emicizumab ProphylaxisTreatment being tested

    Prevention Trial, Arm B: Emicizumab 1.5 mg/kg weekly (following 4-wk induction at 3 mg/kg weekly) will be administered by subcutaneous injection in previously untreated children with severe hemophilia A beginning before the first bleed and continued for up to 48 weeks.

  • Eloctate ITI plus EmicizumabTreatment being tested

    Eradication Trial, Arm A: Eloctate 100 IU/kg every other day will be administered by intravenous infusion as immune tolerance plus Emicizumab 1.5 mg/kg weekly by subcutaneous injection in previously treated children and adults with severe hemophilia A and high-titer inhibitors and continued for up to 48 weeks.

  • Eloctate ITI AloneExisting treatment, for comparison

    Eradication Trial, Arm B: Eloctate 100 IU/kg every other day will be administered by intravenous infusion as immune tolerance alone in previously treated children and adults with severe hemophilia A and high-titer inhibitors and continued for up to 48 weeks.

    Treatment: Eloctate ITI

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase III INHIBIT Platform: Prevention Trial, Eloctate vs Emicizumab to Prevent Inhibitors; Eradication Trial: Eloctate Immune Tolerance (ITI) Plus Emicizumab vs vs Eloctate ITI Alone to Eradicate Inhibitors in Severe Hemophilia A
Publications
Record updated
20 August 2019